Ignite Creation Date:
2024-07-17 @ 11:02 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06464068
Status:
RECRUITING
Last Update Posted:
2024-06-18
First Post:
2024-06-07
Brief Title:
AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA
Sponsor:
Gruppo Oncologico Italiano di Ricerca Clinica
Organization:
Gruppo Oncologico Italiano di Ricerca Clinica
Organization Data
Organization:
Gruppo Oncologico Italiano di Ricerca Clinica
Class:
OTHER
Study ID:
GOIRC-01-2021
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Gruppo Oncologico Italiano di Ricerca Clinica
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None